Associated Papers
KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma.
Norton C et al.
Jama Network Open, 2025
Ras, RhoA, and vascular pharmacology in neurodevelopment and aging.
Nussinov R et al.
Neurochemistry International, 2024
Cooperative genomic lesions in HRAS-mutant cancers predict resistance to farnesyltransferase inhibitors.
Nigam A et al.
Oncogene, 2024
GTP-Bound N-Ras Conformational States and Substates Are Modulated by Membrane and Point Mutation.
Farcas A et al.
International Journal of Molecular Sciences, 2024
KRAS: A Druggable Target in Colon Cancer Patients.
Negri F et al.
International Journal of Molecular Sciences, 2022
Mutational landscape of K-Ras substitutions at 12th position-a systematic molecular dynamics approach.
S UK et al.
Journal of Biomolecular Structure & Dynamics, 2022
Enhanced interpretation of 935 hotspot and non-hotspot RAS variants using evidence-based structural bioinformatics.
Tripathi S et al.
Computational and Structural Biotechnology Journal, 2022
Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy.
Baleeiro RB et al.
Frontiers in Immunology, 2022
Anticancer drug resistance: An update and perspective.
Nussinov R et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2021
Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo.
Sakamoto K et al.
Scientific Reports, 2020
KRAS: From undruggable to a druggable Cancer Target.
Uprety D et al.
Cancer Treatment Reviews, 2020
KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K-MAPK1 inhibition.
Janardhan HP et al.
The Journal of Experimental Medicine, 2020
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.
Testa U et al.
Medical Sciences (basel, Switzerland), 2020
Costello syndrome: Clinical phenotype, genotype, and management guidelines.
Gripp KW et al.
American Journal of Medical Genetics. Part A, 2019
Rap2 and TNIK control Plexin-dependent tiled synaptic innervation in C. elegans.
Chen X et al.
Elife, 2018
Differentiating the pre-hydrolysis states of wild-type and A59G mutant HRas: An insight through MD simulations.
Sharma N et al.
Computational Biology and Chemistry, 2017
Aurora kinase A interacts with H-Ras and potentiates Ras-MAPK signaling.
Umstead M et al.
Oncotarget, 2017
The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway.
Stevenson DA et al.
American Journal of Medical Genetics. Part A, 2016
Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.
Redig AJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B.
Lu S et al.
Scientific Reports, 2016
MgcRacGAP inhibition stimulates JAK-dependent STAT3 activity.
van Adrichem AJ et al.
Febs Letters, 2015
HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.
Omrani A et al.
Molecular Psychiatry, 2015
Why does mutation of Gln61 in Ras by the nitro analog NGln maintain activity of Ras-GAP in hydrolysis of guanosine triphosphate?
Khrenova MG et al.
Proteins, 2015
Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation.
Winter JJ et al.
Journal of Medicinal Chemistry, 2015
KRAS mutation testing in clinical practice.
Perincheri S et al.
Expert Review of Molecular Diagnostics, 2015
Modeling the role of G12V and G13V Ras mutations in the Ras-GAP-catalyzed hydrolysis reaction of guanosine triphosphate.
Khrenova MG et al.
Biochemistry, 2014
Kinetic mechanisms of mutation-dependent Harvey Ras activation and their relevance for the development of Costello syndrome.
Wey M et al.
Biochemistry, 2013
C. elegans PVF-1 inhibits permissive UNC-40 signalling through CED-10 GTPase to position the male ray 1 sensillum.
Dalpe G et al.
Development (cambridge, England), 2013
Crystal structures of the state 1 conformations of the GTP-bound H-Ras protein and its oncogenic G12V and Q61L mutants.
Muraoka S et al.
Febs Letters, 2012
A vertically stacked, polymer, microfluidic point mutation analyzer: rapid high accuracy detection of low-abundance K-ras mutations.
Han K et al.
Analytical Biochemistry, 2011
Mutations in K-ras and epidermal growth factor receptor expression in Korean patients with stages III and IV colorectal cancer.
Lee WS et al.
International Journal of Surgical Pathology, 2011
Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders.
Gremer L et al.
Human Mutation, 2011
Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas.
Lo HW
Current Cancer Drug Targets, 2010
The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors.
Kraniak JM et al.
Molecular and Cellular Biochemistry, 2010
Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.
Smith G et al.
British Journal of Cancer, 2010
p120-Ras GTPase activating protein (RasGAP): a multi-interacting protein in downstream signaling.
Pamonsinlapatham P et al.
Biochimie, 2009
Gap-junction channels dysfunction in deafness and hearing loss.
Martínez AD et al.
Antioxidants & Redox Signaling, 2009
Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
Tidyman WE et al.
Expert Reviews in Molecular Medicine, 2008
Phospholipase C epsilon suppresses integrin activation.
Lad Y et al.
The Journal of Biological Chemistry, 2006
PARG1, a protein-tyrosine phosphatase-associated RhoGAP, as a putative Rap2 effector.
Myagmar BE et al.
Biochemical and Biophysical Research Communications, 2005
Conformational states of Ras complexed with the GTP analogue GppNHp or GppCH2p: implications for the interaction with effector proteins.
Spoerner M et al.
Biochemistry, 2005
Role of the Rap1 GTPase in astrocyte growth regulation.
Apicelli AJ et al.
Glia, 2003
Ras superfamily monomeric G proteins in carcinoma cell motility.
Oxford G et al.
Cancer Letters, 2003
Oncogenic insertional mutations in the P-loop of Ras are overactive in MAP kinase signaling.
Klockow B et al.
Oncogene, 2000
RGS14 is a novel Rap effector that preferentially regulates the GTPase activity of galphao.
Traver S et al.
The Biochemical Journal, 2000
Loss of the effector function in a transducin-alpha mutant associated with Nougaret night blindness.
Muradov KG et al.
The Journal of Biological Chemistry, 2000
Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression.
Al-Mulla F et al.
The Journal of Pathology, 1999
Guanine nucleotide binding properties of Rac2 mutant proteins and analysis of the responsiveness to guanine nucleotide dissociation stimulator.
Xu X et al.
Biochemistry, 1997
Identification of neurofibromin mutants that exhibit allele specificity or increased Ras affinity resulting in suppression of activated ras alleles.
Morcos P et al.
Molecular and Cellular Biology, 1996
Inhibition of Ras/Raf interaction by anti-oncogenic mutants of neurofibromin, the neurofibromatosis type 1 (NF1) gene product, in cell-free systems.
Mori S et al.
The Journal of Biological Chemistry, 1995